Paper33800296
Effect of N-Acetylcysteine Administration on 30-Day Mortality in Critically Ill Patients with Septic Shock Caused by Carbapenem-Resistant Klebsiella pneumoniae and Acinetobacter baumannii: A Retrospective Case-Control Study.
Oliva A and 8 others. Antibiotics (Basel), 2021. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. Effect of N-Acetylcysteine Administration on 30-Day Mortality in Critically Ill Patients with Septic Shock Caused by Carbapenem-Resistant Klebsiella pneumoniae and Acinetobacter baumannii: A Retrospective Case-Control Study. Papers, record 33800296. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33800296
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Effect of N-Acetylcysteine Administration on 30-Day Mortality in Critically Ill Patients with Septic Shock Caused by Carbapenem-Resistant Klebsiella pneumoniae and Acinetobacter baumannii: A Retrospective Case-Control Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 401831 | Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. | J Clin Microbiol | 1977 | https://conductscience.org/library/papers/401831 | PubMed |
| 2 | 33213070 | Usefulness of Antioxidants as Adjuvant Therapy for Septic Shock: A Randomized Clinical Trial. | Medicina (Kaunas) | 2020 | https://conductscience.org/library/papers/33213070 | PubMed |
| 3 | 15037211 | Immune cells: free radicals and antioxidants in sepsis. | Int Immunopharmacol | 2004 | https://conductscience.org/library/papers/15037211 | PubMed |
| 4 | 25900159 | Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. | J Antimicrob Chemother | 2015 | https://conductscience.org/library/papers/25900159 | PubMed |
| 5 | 18044098 | Role of N-acetylcysteine in the management of COPD. | Int J Chron Obstruct Pulmon Dis | 2006 | https://conductscience.org/library/papers/18044098 | PubMed |
| 6 | 19732754 | N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. | Biochem Pharmacol | 2010 | https://conductscience.org/library/papers/19732754 | PubMed |
| 7 | 14605526 | The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis. | Crit Care Med | 2003 | https://conductscience.org/library/papers/14605526 | PubMed |
| 8 | 27989244 | Clinical Risk Score for Prediction of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Bloodstream Isolates. | Infect Control Hosp Epidemiol | 2017 | https://conductscience.org/library/papers/27989244 | PubMed |
| 9 | 26751198 | Emerging drugs for the treatment of sepsis. | Expert Opin Emerg Drugs | 2016 | https://conductscience.org/library/papers/26751198 | PubMed |
| 10 | 10638663 | Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. | Shock | 2000 | https://conductscience.org/library/papers/10638663 | PubMed |
| 11 | 14527779 | Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. | Int J Antimicrob Agents | 2003 | https://conductscience.org/library/papers/14527779 | PubMed |
| 12 | 31145911 | Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. | J Infect | 2019 | https://conductscience.org/library/papers/31145911 | PubMed |
| 13 | 27492531 | The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. | Respir Med | 2016 | https://conductscience.org/library/papers/27492531 | PubMed |
| 14 | 11153617 | N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study. | Crit Care Med | 2000 | https://conductscience.org/library/papers/11153617 | PubMed |
| 15 | 14605544 | Antioxidant therapy for severe sepsis: promise and perspective. | Crit Care Med | 2003 | https://conductscience.org/library/papers/14605544 | PubMed |
| 16 | 26903338 | The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). | JAMA | 2016 | https://conductscience.org/library/papers/26903338 | PubMed |
| 17 | 31102529 | N-acetylcysteine blocks SOS induction and mutagenesis produced by fluoroquinolones in Escherichia coli. | J Antimicrob Chemother | 2019 | https://conductscience.org/library/papers/31102529 | PubMed |
| 18 | 24970742 | Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. | J Antimicrob Chemother | 2014 | https://conductscience.org/library/papers/24970742 | PubMed |
| 19 | 26438224 | Task force on management and prevention of Acinetobacter baumannii infections in the ICU. | Intensive Care Med | 2015 | https://conductscience.org/library/papers/26438224 | PubMed |
| 20 | 29846610 | In vitro synergism of colistin in combination with N-acetylcysteine against Acinetobacter baumannii grown in planktonic phase and in biofilms. | J Antimicrob Chemother | 2018 | https://conductscience.org/library/papers/29846610 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41312188 | N-acetylcysteine in paediatrics: a review of efficacy, safety and dosing strategies in respiratory care. | Drugs Context | 2025 | https://conductscience.org/library/papers/41312188 | PubMed |
| 41293242 | Recent advances in understanding oxidative stress in sepsis: pathogenic roles and antioxidant therapeutic prospects - a narrative review. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41293242 | PubMed |
| 40060738 | Targeting sepsis through inflammation and oxidative metabolism. | World J Crit Care Med | 2025 | https://conductscience.org/library/papers/40060738 | PubMed |
| 39575187 | Editorial: New therapeutic strategies against carbapenem-resistant gram-negative bacteria. | Front Microbiol | 2024 | https://conductscience.org/library/papers/39575187 | PubMed |
| 39355778 | Antibiotics-free compounds for managing carbapenem-resistant bacteria; a narrative review. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39355778 | PubMed |
| 38644822 | The effects of antioxidant supplementation on short-term mortality in sepsis patients. | Heliyon | 2024 | https://conductscience.org/library/papers/38644822 | PubMed |
| 38304194 | Editorial: Enterobacteriaceae antimicrobial agents and resistance: relationship with the therapeutic approach, volume II. | Front Cell Infect Microbiol | 2024 | https://conductscience.org/library/papers/38304194 | PubMed |
| 37425994 | Acinetobacter baumannii in the critically ill: complex infections get complicated. | Front Microbiol | 2023 | https://conductscience.org/library/papers/37425994 | PubMed |
| 37174730 | Randomized Clinical Trial of Antioxidant Therapy Patients with Septic Shock and Organ Dysfunction in the ICU: SOFA Score Reduction by Improvement of the Enzymatic and Non-Enzymatic Antioxidant System. | Cells | 2023 | https://conductscience.org/library/papers/37174730 | PubMed |
| 36506890 | Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study. | JAC Antimicrob Resist | 2022 | https://conductscience.org/library/papers/36506890 | PubMed |
| 36439795 | Carbapenem-resistant Acinetobacter baumannii: A challenge in the intensive care unit. | Front Microbiol | 2022 | https://conductscience.org/library/papers/36439795 | PubMed |
| 36410267 | N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions. | J Infect Public Health | 2022 | https://conductscience.org/library/papers/36410267 | PubMed |
| 35203827 | High Activity of N-Acetylcysteine in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae and Acinetobacter baumannii. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35203827 | PubMed |
| 34833436 | The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit. | Medicina (Kaunas) | 2021 | https://conductscience.org/library/papers/34833436 | PubMed |
| 34595135 | Editorial: Enterobacteriaceae Antimicrobial Agents and Resistance: Relationship With the Therapeutic Approach. | Front Cell Infect Microbiol | 2021 | https://conductscience.org/library/papers/34595135 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CXCL8 | 3576 | PubTator's text mining | https://conductscience.org/library/genes/3576 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33800296
GET https://conductscience.org/api/papers/v1/33800296/references?page=2